A5021837801- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Blood transfusion and management
- Venous Thromboembolism Diagnosis and Management
- Blood donation and transfusion practices
- Cardiac and Coronary Surgery Techniques
- Long-Term Effects of COVID-19
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- COVID-19 Impact on Reproduction
- Cardiac, Anesthesia and Surgical Outcomes
- Heparin-Induced Thrombocytopenia and Thrombosis
- Atrial Fibrillation Management and Outcomes
- Erythropoietin and Anemia Treatment
- Cardiovascular and Diving-Related Complications
- COVID-19 epidemiological studies
- Cardiac Arrest and Resuscitation
- Intramuscular injections and effects
- Diabetes and associated disorders
- Coronary Artery Anomalies
- Cardiac tumors and thrombi
- Aortic Disease and Treatment Approaches
- Patient-Provider Communication in Healthcare
- Kawasaki Disease and Coronary Complications
- Hemophilia Treatment and Research
- Congenital Diaphragmatic Hernia Studies
Mayo Clinic in Florida
2024-2025
Mayo Clinic
2019-2024
Mayo Clinic in Arizona
2017-2023
Faculty of 1000 (United States)
2023
RELX Group (United States)
2023
Cooper Medical School of Rowan University
2021
Johns Hopkins University
2021
Cooper University Health Care
2021
WinnMed
2021
Trinity College Dublin
2010
BackgroundConvalescent plasma has been widely used to treat coronavirus disease 2019 (Covid-19) under the presumption that such contains potentially therapeutic antibodies severe acute respiratory syndrome 2 (SARS-CoV-2) can be passively transferred recipient. Whether convalescent with high antibody levels rather than low is associated a lower risk of death unknown.MethodsIn retrospective study based on U.S. national registry, we determined anti–SARS-CoV-2 IgG in hospitalized adults...
BACKGROUND. Convalescent plasma is the only antibody-based therapy currently available for patients with coronavirus disease 2019 (COVID-19). It has robust historical precedence and sound biological plausibility. Although promising, convalescent not yet been shown to be safe as a treatment COVID-19.
Abstract Importance Passive antibody transfer is a longstanding treatment strategy for infectious diseases that involve the respiratory system. In this context, human convalescent plasma has been used to treat coronavirus disease 2019 (COVID-19), but efficacy remains uncertain. Objective To explore potential signals of COVID-19 plasma. Design Open-label, Expanded Access Program (EAP) patients with Setting Multicenter, including 2,807 acute care facilities in US and territories. Participants...
Background: Convalescent plasma is the only antibody based therapy currently available for COVID-19 patients. It has robust historical precedence and sound biological plausibility. Although promising, convalescent not yet been shown to be safe as a treatment COVID-19. Methods: Thus, we analyzed key safety metrics after transfusion of ABO-compatible human in 5,000 hospitalized adults with severe or life threatening COVID-19, 66% intensive care unit, part US FDA Expanded Access Program plasma....
The United States (US) Expanded Access Program (EAP) to coronavirus disease 2019 (COVID-19) convalescent plasma was initiated in response the rapid spread of severe acute respiratory syndrome 2 (SARS-CoV-2), causative agent COVID-19. While randomized clinical trials were various stages development and enrollment, there an urgent need for widespread access potential therapeutic agents. objective this study is report on demographic, geographical, chronological characteristics patients EAP, key...
Abstract Successful therapeutics and vaccines for coronavirus disease 2019 (COVID-19) have harnessed the immune response to severe acute respiratory syndrome 2 (SARS-CoV-2). Evidence that SARS-CoV-2 exists as locally evolving variants suggests immunological differences may impact effectiveness of antibody-based treatments such convalescent plasma vaccines. Considering near-sourced likely reflects antigenic composition local viral strains, we hypothesize has a higher efficacy, defined by...
Warner, Matthew A. MD; Klompas, Allan M. MBBCh, BAO; van Buskirk, Camille MD Author Information
Neuronal cell loss underlies the pathological decline in cognition and memory associated with Alzheimer disease (AD). Recently, targeting endocannabinoid system AD has emerged as a promising new approach to treatment. Studies have identified neuroprotective roles for endocannabinoids against key events brain, including death by apoptosis. Elucidation of apoptotic pathway evoked β-amyloid (Aβ) is thus important development therapeutic strategies that can thwart Aβ toxicity preserve viability....
Background Delayed cold storage of room temperature platelets may extend shelf life from 5 to 14 days. The study hypothesized that the use delayed cold-stored in cardiac surgery would be associated with decreased postoperative platelet count increments but similar transfusion and clinical outcomes compared temperature-stored platelets. Methods This is an observational cohort adults transfused intraoperatively during elective between April 2020 May 2021. Intraoperative were either or based on...
Transesophageal echocardiography (TEE) is increasingly used for intraoperative management during orthotopic liver transplantation. Proficient TEE use requires skill and knowledge to accurately assess the hemodynamic status guide clinical management. Currently there are no educational tracks specifically focused on perioperative transplant barriers obtaining basic certification exist.A 4-hour simulation-based learning (SBL) course was provided improve anesthesiologist skill. Learners received...
Convalescent plasma is used to treat COVID-19. There are theoretical concerns about the impact of pro-coagulant factors in convalescent on coagulation cascade particularly among patients with severe The aim this study was evaluate profile COVID-19 plasma. Clotting times and factor assays were compared between fresh frozen plasma, pathogen-reduced Measurements included prothrombin time, activated partial thromboplastin thrombin fibrinogen, D-dimer, von Willebrand activity, antigen, II, V,...
Abstract Background The United States (US) Expanded Access Program (EAP) to COVID-19 convalescent plasma was initiated in response the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causative agent disease-2019 (COVID-19). While randomized clinical trials were various stages development and enrollment, there an urgent need for widespread access potential therapeutic agents particularly vulnerable racial ethnic minority populations who disproportionately...
Pulmonary alveolar proteinosis (PAP) is a rare syndrome in which phospholipoproteinaceous matter accumulates the alveoli leading to compromised gas exchange. Whole-lung lavage considered gold standard for severe autoimmune PAP and offers favorable long-term outcomes. In this case report, we describe perioperative management procedural specifics of patient undergoing WLL an anesthesiologist serves as proceduralist separate provides anesthesia care patient.
<br>Heparin-induced thrombocytopenia type II is a rare but devastating complication of heparin exposure. We review case 66-year-old female who underwent aortic valve surgery requiring venoarterial extracorporeal membranous oxygenation (ECMO) support postoperatively. She subsequently developed acute renal failure due to bilateral vein thromboses and was found have platelet factor 4/heparin antibodies diagnosed with heparin-induced (HIT). transitioned nonheparin anticoagulation her improved....
Abstract Background Some patients express concerns regarding receipt of allogeneic blood transfusions from donors potentially vaccinated against SARS‐CoV‐2 (COVID‐19). However, limited information exists about patients' expression these or how to address them during the transfusion consent process. In this study, we describe our experience working collaboratively with vaccine‐related prior elective surgery, summarizing treatment decisions and clinical outcomes. Study Design Methods This...
Preoperative anemia is common and associated with worse outcomes in cardiac surgery including acute kidney injury, red blood cell transfusion, cardiovascular complications, stroke, infection, death. Patient management programs, which include dedicated clinical programs to diagnose treat advance of (ie, preoperative programs), have been highlighted as a means optimize the health each patient, thereby decreasing risk for allogeneic transfusion improving outcomes. However, there remain...
ABSTRACT Although rare, iatrogenic aortocoronary arteriovenous fistulae (ACAVF) occur when a coronary graft is mistakenly anastomosed to an epicardial vein rather than its intended arterial target. Patients may be asymptomatic, demonstrate angina, dyspnea, arrhythmias, syncope, or diminished exercise capacity, and have wide pulse pressures with evidence of steal. A thorough insight into the disordered anatomy critical safely manage patient for redo cardiac surgery, especially attempting...
AL amyloidosis is associated with acquired factor X (FX) deficiency. Experience related to its management limited case reports and series using prothrombin complex concentrate, fresh frozen plasma, plasma exchange, recombinant activated seven, desmopressin variable efficacy. FX concentrate has not been widely used in management.We report our experience the perioperative use of (Coagadex) two patients amyloidosis-associated deficiency requiring surgery, their individual pharmacokinetic...